Pioglitazon
Изглед
Klinički podaci | |
---|---|
Prodajno ime | Actos, Actost, Glustin |
Drugs.com | Monografija |
Način primene | Oralno |
Farmakokinetički podaci | |
Poluvreme eliminacije | 3-7 h |
Identifikatori | |
CAS broj | 111025-46-8 |
ATC kod | A10BG03 (WHO) |
PubChem | CID 4829 |
IUPHAR/BPS | 2694 |
DrugBank | DB01132 |
ChemSpider | 4663 |
KEGG | C07675 |
ChEBI | CHEBI:8228 |
ChEMBL | CHEMBL595 |
Hemijski podaci | |
Formula | C19H20N2O3S |
Molarna masa | 356,439 |
| |
| |
Fizički podaci | |
Tačka topljenja | 183—184 °C (361—363 °F) |
Pioglitazon je organsko jedinjenje, koje sadrži 19 atoma ugljenika i ima molekulsku masu od 356,439 Da.[1][2][3][4][5]
Osobine
[уреди | уреди извор]Osobina | Vrednost |
---|---|
Broj akceptora vodonika | 5 |
Broj donora vodonika | 1 |
Broj rotacionih veza | 7 |
Particioni koeficijent[6] (ALogP) | 3,9 |
Rastvorljivost[7] (logS, log(mol/L)) | -5,5 |
Polarna površina[8] (PSA, Å2) | 93,6 |
Reference
[уреди | уреди извор]- ^ Colca, J. R.; McDonald, W. G.; Waldon, D. J.; Leone, J. W.; Lull, J. M.; Bannow, C. A.; Lund, E. T.; Mathews, W. R. (2004). „Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe”. American Journal of Physiology. Endocrinology and Metabolism. 286 (2): E252—60. PMID 14570702. doi:10.1152/ajpendo.00424.2003.
- ^ Paddock, M. L.; Wiley, S. E.; Axelrod, H. L.; Cohen, A. E.; Roy, M.; Abresch, E. C.; Capraro, D.; Murphy, A. N.; Nechushtai, R.; Dixon, J. E.; Jennings, P. A. (2007). „MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone”. Proceedings of the National Academy of Sciences of the United States of America. 104 (36): 14342—14347. Bibcode:2007PNAS..10414342P. PMC 1963346 . PMID 17766440. doi:10.1073/pnas.0707189104 .
- ^ Lincoff, A. M.; Wolski, K.; Nicholls, S. J.; Nissen, S. E. (2007-09-12). „Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials”. JAMA. 298 (10): 1180—8. PMID 17848652. doi:10.1001/jama.298.10.1180.
- ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura
[уреди | уреди извор]- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
[уреди | уреди извор]
Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |